Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Physiologic solution, specifically 0.9% sodium chloride (NaCl), was utilized as the placebo control in a Phase II randomized, double-blind trial conducted by the Università Politecnica delle Marche. The study aimed to evaluate the effects of IgM-enriched immunoglobulins (Pentaglobin) on sublingual microcirculation in patients diagnosed with severe sepsis or septic shock. In this clinical context, the solution was administered intravenously at a dosage of 5 mL/kg per day for a duration of 72 hours. While it serves as a standard isotonic crystalloid for fluid maintenance, its role in this specific trial was to provide a volume-matched comparator to assess the efficacy of the active immunoglobulin therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on physiologic solution.